368 related articles for article (PubMed ID: 23178987)
1. Osteoporosis regulation by salubrinal through eIF2α mediated differentiation of osteoclast and osteoblast.
He L; Lee J; Jang JH; Sakchaisri K; Hwang J; Cha-Molstad HJ; Kim KA; Ryoo IJ; Lee HG; Kim SO; Soung NK; Lee KS; Kwon YT; Erikson RL; Ahn JS; Kim BY
Cell Signal; 2013 Feb; 25(2):552-60. PubMed ID: 23178987
[TBL] [Abstract][Full Text] [Related]
2. Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha.
Hamamura K; Tanjung N; Yokota H
J Bone Miner Metab; 2013 Nov; 31(6):618-28. PubMed ID: 23536193
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in silico analysis of an inhibitory mechanism of osteoclastogenesis by salubrinal and guanabenz.
Hamamura K; Chen A; Tanjung N; Takigawa S; Sudo A; Yokota H
Cell Signal; 2015 Feb; 27(2):353-62. PubMed ID: 25435425
[TBL] [Abstract][Full Text] [Related]
4. Role of endoplasmic reticulum stress in disuse osteoporosis.
Li J; Yang S; Li X; Liu D; Wang Z; Guo J; Tan N; Gao Z; Zhao X; Zhang J; Gou F; Yokota H; Zhang P
Bone; 2017 Apr; 97():2-14. PubMed ID: 27989543
[TBL] [Abstract][Full Text] [Related]
5. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
[TBL] [Abstract][Full Text] [Related]
7. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
[TBL] [Abstract][Full Text] [Related]
8. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.
Han SY; Lee KH; Kim YK
Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250
[TBL] [Abstract][Full Text] [Related]
9. Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells.
Yokota H; Hamamura K; Chen A; Dodge TR; Tanjung N; Abedinpoor A; Zhang P
BMC Musculoskelet Disord; 2013 Jul; 14():197. PubMed ID: 23816340
[TBL] [Abstract][Full Text] [Related]
10. eIF2α signaling regulates autophagy of osteoblasts and the development of osteoclasts in OVX mice.
Li J; Li X; Liu D; Hamamura K; Wan Q; Na S; Yokota H; Zhang P
Cell Death Dis; 2019 Dec; 10(12):921. PubMed ID: 31801950
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
Cao B; Dai X; Wang W
J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
[TBL] [Abstract][Full Text] [Related]
12. Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.
Yamashita T; Uehara S; Udagawa N; Li F; Kadota S; Esumi H; Kobayashi Y; Takahashi N
PLoS One; 2014; 9(1):e85878. PubMed ID: 24465763
[TBL] [Abstract][Full Text] [Related]
13. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
[TBL] [Abstract][Full Text] [Related]
14. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
15. Isoproterenol Increases RANKL Expression in a ATF4/NFATc1-Dependent Manner in Mouse Osteoblastic Cells.
Baek K; Park HJ; Baek JH; Kim HR
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053621
[TBL] [Abstract][Full Text] [Related]
16. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
17. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
Li L; Sapkota M; Gao M; Choi H; Soh Y
Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
[TBL] [Abstract][Full Text] [Related]
18. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.
Yamashita T; Yao Z; Li F; Zhang Q; Badell IR; Schwarz EM; Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF
J Biol Chem; 2007 Jun; 282(25):18245-18253. PubMed ID: 17485464
[TBL] [Abstract][Full Text] [Related]
20. Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.
Han SY; Kim YK
Am J Chin Med; 2019; 47(2):439-455. PubMed ID: 30827151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
